Grand Pharmaceutical Group Limited (0512.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

Industry: Medical - Pharmaceuticals
Sector: Healthcare
Headquarters: HK
CEO: Chao Zhou
Listed since: May 11, 2004
Employees: 12,614

Market position

Day range

Current HK$5.24

HK$5.21HK$5.36

52-week range

Current HK$5.24

HK$4.53HK$9.88

Open: HK$5.36
Previous close: HK$5.255
Volume: 1.71M; 0.31× average
Average volume: 5.56M; Average daily volume
Market cap: 18.35B HKD
Beta: 0.7; Market reference 1
50-day average: HK$5.1197; +2.35% above average
200-day average: HK$6.7004; -21.80% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 31.05B HKD
P/E (TTM): 14.95×
P/B (TTM): 1.08×
P/S (TTM): 1.49×
EV / EBITDA: 13.44×
Earnings yield: 4.51%
Free cash flow yield: 2.82%
Dividend yield: 3.23%

Profitability & efficiency

Gross margin: 55.20%
Operating margin: 8.49%
Net margin: 10.10%
Return on equity: 7.29%
Return on assets: 4.57%
Return on invested capital: 3.82%

Financial health

Debt / equity: 0.28×
Current ratio: 1.14×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

12.28B HKD+5.48%

Operating income

1.04B HKD-52.00%

Net income

1.24B HKD-49.73%

Metric (HKD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	12.28B HKD	11.64B HKD	10.53B HKD	9.56B HKD	8.6B HKD
Cost of goods sold	5.5B HKD	4.91B HKD	4.01B HKD	3.61B HKD	3.35B HKD
Gross profit	6.78B HKD	6.74B HKD	6.52B HKD	5.95B HKD	5.25B HKD
Research and development	502.89M HKD	588.14M HKD	571.99M HKD	531.92M HKD	331.42M HKD
Selling, general, and administrative	5.2B HKD	4.62B HKD	3.29B HKD	3.4B HKD	3.31B HKD
Operating expenses	5.74B HKD	4.57B HKD	3.86B HKD	3.43B HKD	3.23B HKD
Interest income	7.37M HKD	6.31M HKD	7.75M HKD	19.81M HKD	74.95M HKD
Interest expense	162.34M HKD	180.24M HKD	205.15M HKD	137.49M HKD	92.96M HKD
Depreciation and amortization	542.84M HKD	503.75M HKD	392.21M HKD	394.91M HKD	339.52M HKD
Operating income	1.04B HKD	2.17B HKD	2.66B HKD	2.52B HKD	2.02B HKD
Net income	1.24B HKD	2.47B HKD	1.88B HKD	2.08B HKD	2.4B HKD